Candesartan cilexetil
As of the edition of 20 October 2026, Candesartan cilexetil is a small molecule: marketed, first approved in 1998 (FR); acts on AGTR1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1999
- Kind
- Small molecule
- Brand name
- Atacand
- First approved
- 7 January 1998 (FR)
- Approvals on record
- 19 in 4 regions
- Holder of the most recent approval
- Takeda; 5 holders in all
- Registered trials
- 50, 3 stopped early
- Disease areas
- Heart and blood vessels; Nervous system; Pregnancy and women's health; Urinary and reproductive; Chemically induced; Hormones
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route B because of this drug.
Companies on route B for this drug
In the product2 companies are on route B because of Candesartan cilexetil.
See the 2 companies on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| AGTR1 | Type-1 angiotensin II receptor | P30556 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 6 | 6 | 0 | 0 |
| Phase 1 | 13 | 10 | 0 | 0 |
| Phase 2 | 6 | 3 | 0 | 2 |
| Phase 3 | 16 | 14 | 0 | 1 |
| Phase 4 | 9 | 7 | 0 | 0 |
| All trials | 50 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| AstraZeneca | Earlier holder | 1998 to now |
| Cheplapharm Arzneimittel | Applicant | 1998 to now |
| Takeda | Applicant and Lead sponsor of trials | 1999 to now |
| ANI Pharmaceuticals | Acquired holder | 2018 to now |
| ASKA Pharmaceutical | Later holder |